Drug intelligence / Profile preview

zifaxaban

Development stage: Unknown
Lead developer: Tianjin Institute of Pharmaceutical Research
Modality: Small Molecules
Administration: Oral

Overview

Zifaxaban (also known as zhifeishaban, Zifa01, or TY-602) is an orally active, direct, and selective small molecule inhibitor of coagulation Factor Xa (FXa). Developed by the Tianjin Institute of Pharmaceutical Research, zifaxaban competitively inhibits human FXa with high affinity (IC50 of 11.1 nM) and exhibits greater than 10,000-fold selectivity over other serine proteases. It is being developed as an oral anticoagulant for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism. Clinical trials, including Phase II studies in China, are evaluating its efficacy, safety, pharmacokinetics, and pharmacodynamics in patients with acute symptomatic deep vein thrombosis.

Other names: zhifeishaban知非沙班

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on zifaxaban.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zifaxaban.

Explore the full profile